このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

視神経脊髄炎スペクトラム障害患者におけるBAT4406F注射の臨床試験

2026年9月29日 更新者:Bio-Thera Solutions

視神経脊髄炎系統疾患患者におけるBAT4406F注射の有効性と安全性を評価する第II/III相試験

This is a phase II/III multicenter, randomized, double-blind, placebo-controlled study, to investigate the efficacy and safety of BAT4406F injection in patients with neuromyelitis optica lineage disease (NMOSD) who are positive for aquaporin 4 antibody (AQP4-IgG) .

調査の概要

状態

積極的、募集していない

詳細な説明

This study was a phase II/III multicenter, randomized, double-blind, placebo-controlled study, which was divided into screening period (4 weeks) , randomized control period (RCP) , and open-label period (Olp)A total of 162 subjects were enrolled during the screening period and randomly assigned 2:1 to either the BAT4406F group or the placebo group after randomization on Day 1 of the RCP, subjects would receive BAT4406F (at a dose of 500mg) or placebo, intravenously, at D 1 and D 182, respectively.

If any of the following conditions occur, subjects can enter OLP from RCP: 1. Subjects who complete the 52-week RCP study without recurrence of NMOSD can enter Olp within 14 days after the end of the RCP study. 2. In the stage of RCP, NMOSD recurred. After rescue therapy, the patients with stable condition could enter OLP within 28 days after diagnosis. Subjects continued to participate in the RCP study if they were not identified by CEC as having a relapse upon examination. 3. When a protocol-defined first relapse event of 35 cases is observed, or when all 162 subjects have completed randomization and 12 months have elapsed since the first dose in the last of these subjects, or when recommended by the Independent Data Monitoring Committee (IDMC) , the RCP study should be stopped for enrolled subjects, and all enrolled subjects at the RCP stage should stop the RCP study within 14 days of entry into OLP, after which subjects will receive BAT4406F injection at the same dose as RCP, at d 1 of OLP. After termination of the RCP study with BAT4406F every 6 months, subjects were given the option of enrolling in the OLP study.

研究の種類

介入

入学 (推定)

162

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Baotou、中国
        • The First Affiliated Hospital of the Baotou Medical College of Inner Mongolia University of Science and Technology
      • Beijing、中国
        • Beijing Hospital
      • Beijing、中国
        • China-japan friendship Hospital
      • Beijing、中国
        • The first hospital of Peking University
      • Changsha、中国
        • The Central South University Xiang Ya Hospital
      • Changsha、中国
        • Xiangya 2nd hospital of central south university
      • Chongqing、中国
        • First affiliated hospital of chongqing medical university
      • Dalian、中国
        • The first affiliated hospital of Dalian Medical University
      • Fuzhou、中国
        • First affiliated hospital of fujian medical university
      • Guangzhou、中国
        • The first hospital affiliated to sun yat-sen university
      • Guangzhou、中国
        • The third hospital affiliated to sun yat-sen university
      • Guangzhou、中国
        • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
      • Guangzhou、中国
        • The first People's Hospital of Guangzhou
      • Hangzhou、中国
        • People's Hospital of Zhejiang province
      • Hefei、中国
        • Anhui Provincial Hospital
      • Hefei、中国
        • Second Affiliated Hospital of Anhui Medical University
      • Jinan、中国
        • Shandong University Qilu Hospital
      • Jingzhou、中国
        • Jingzhou Central Hospital
      • Kunming、中国
        • First Affiliated Hospital of the Kunming Medical University
      • Nanchang、中国
        • Second Affiliated Hospital of Nanchang University
      • Nanchong、中国
        • Affiliated Hospital of North Sichuan Medical College
      • Nanjing、中国
        • Drum Tower Hospital affiliated to Medical College of Nanjing University
      • Nanjing、中国
        • The Chinese people's liberation army general hospital in eastern theater
      • Nanjing、中国
        • Southeast university affiliated zhongda hospital
      • Nantong、中国
        • The first People's Hospital of Nantong
      • Qingdao、中国
        • Qingdao municipal hospital
      • Shanghai、中国
        • Mount Hua Hospital affiliated to Fudan University
      • Shanghai、中国
        • Shuguang hospital affiliated to Shanghai University of Traditional Chinese medicine
      • Shanghai、中国
        • Zhongshan hospital affiliated to Fudan University
      • Shenzhen、中国
        • Shenzhen city people's hospital
      • Shijia Zhuang、中国
        • Second Hebei Medical University Hospital
      • Shijiazhuang、中国
        • The Third Hospital of Hebei Medical University
      • Suzhou、中国
        • The Second Affiliated Hospital of Suzhou University
      • Suzhou、中国
        • First Affiliated Hospital of Suzhou University
      • Taiyuan、中国
        • The first hospital of shanxi medical university
      • Tianjin、中国
        • Tianjin Medical University General Hospital
      • Wenzhou、中国
        • The first hospital affiliated to wenzhou medical college
      • Wuhan、中国
        • Tongji hospital affiliated to tongji medical college huazhong university of science and technology
      • Wuhan、中国
        • Xiehe hospital affiliated to tongji medical college huazhong university of science and technology
      • Wuxi、中国
        • Wuxi city people's hospital
      • Xi'an、中国
        • Second Affiliated Hospital of the People's Liberation Army Air Force Military Medical University
      • Xi'an、中国
        • Xi'an high-tech Hospital Co. , Ltd.
      • Xianyang、中国
        • Yan 'an University Xianyang Hospital Co. , Ltd.
      • Zhengzhou、中国
        • Henan province people's hospital
      • Zhenzhou、中国
        • Zhengzhou university first affiliated hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~65年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Age greater than or equal to the age of 18 and less than or equal to 65 patients, gender not limited;
  2. Met the 2015 international NMO diagnostic panel (IPND) criteria for NMOSD, And AQP4-IGG positive patients
  3. Screening before 2 times at least 2 years experience with clinical records of relapse,or experienced at least 1 clinically documented recurrence within 1 year prior to screening
  4. For subjects who had a relapse before screening, symptoms needed to be stable for at least 4 weeks before randomization
  5. Into the group of former dosage of corticosteroids under 30 mg and prednisone equivalent,and the trial drug must be used within a month after the withdrawal of hormones
  6. The score of EDSS 7 or less
  7. Has the fertility of men and women must agree during treatment and 6 months after the last dose of using effective birth control method;
  8. Agreed to participate in trials, and books to sign the informed consent

Exclusion Criteria:

  1. CD19 + b-cell count below the lower limit of normal, b-cell-scavenger drugs used 6 months before baseline or within 5 half-lives of the drug, whichever is older (including but not limited to Rituximab, enalizumab, etc.) ;

  2. 6 months prior to the baseline used other monoclonal antibody therapy;Baseline used within five half-life before other biological preparation;

  3. Used it for 3 months prior to the baseline McCaw phenol ester, azathioprine and methotrexate;6 months prior to the baseline using cyclophosphamide;Baseline before five half-life

  4. Within a month before the filter used intravenous immunoglobulin (IVIG), plasma exchange (PE);

  5. Within 4 weeks before screening received vaccine or live attenuated;Within 2 weeks before the baseline received inactivated vaccine;Baseline received within 4 weeks before the new coronavirus vaccine

  6. In another clinical study and the baseline from the test drug treatment under three months or 5 half-life of the drug (the long time limit shall prevail);

  7. This test for monoclonal antibody has a history of allergies, known in drug allergy patients;Serious drug allergy or for two or over two kinds of food or drugs;

  8. 6 months prior to screening, except NMOSD need continuous oral or intravenous glucocorticoid dose > 20 mg/day of any more than 21 days

  9. Abnormal liver, kidney and bone marrow reserve

  10. HIV positive at HIV history or enrollment screening; History of hepatitis B Andor hepatitis C or Hepatitis B surface antigen (HBSAG) positivity at screening [ or Hepatitis B core antibody positive, hepatitis B surface antibody negative, Hepatitis B virus deoxynucleotides (HBV DNA) quantification exceeding normal range ] ; Or Hepatitis C virus (HCV) antibody positive [ with HCV-rna quantitation exceeding the normal range ] , Treponema pallidum antibody positive at the time of enrollment;

  11. Comply with any of the following subjects a latent or active TB infection related standards:

    1. Current or past people with active TB;
    2. In history and/or physical examination during filter tip physical signs or symptoms of active TB;
    3. Recent close contact with people with active TB;
    4. At the time of screening, the positive result of TB infected T cells was found. A test could be repeated if the subject's first tb-infected t-cell test result was inconclusive, and the patient was excluded from this study if the test result was inconclusive (or positive) again.
  12. Covid-19 infection was diagnosed with clinical symptoms or signs consistent with 2019 coronavirus (COVID-19) infection (eg, fever, dry cough, dyspnea, sore throat, and fatigue) within 4 weeks before screening or during screening, or upon appropriate laboratory testing (at the discretion of the investigator or in accordance with local regulations) . If COVID-19 infection is confirmed before screening, appropriate laboratory testing is required to confirm that the infection has been cured;

  13. Suffering from metabolic, hematological, renal, hepatic, pulmonary, neuroendocrine, cardiac, infectious, gastrointestinal or other autoimmune diseases, the researchers believe there is an unacceptable risk to patients, or it may affect NMOSD assessment;

  14. According to the researchers, there was a history of drug and alcohol abuse (drinking 14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 125 mL of wine) in the 12 months before screening;

  15. Subjects who are unable to undergo an MRI scan (for example, are allergic to Gd-containing MRI contrast media, have a pacemaker, defibrillator, or other metallic object with internal or external limitations to performing an MRI scan) ;

  16. Pregnant or lactating women, and screening or baseline pregnancy test positive female subjects;

  17. Researchers think that the other does not fit to participate in this study.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:トリプル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Experimental group:BAT4406F

RCP:Intravenous infusion; Dosage:500mg/time; Time of administration:The drug was given at D 1 and D 182 respectively OLP:Intravenous infusion; Dosage:500mg/time; Time of administration: After D1 dosing, Every 6 months to 1 times

Intravenous infusion; Dosage:500mg/time

アクティブコンパレータ:Control group:BAT4406F Placebos

RCP:Intravenous infusion; Dosage:500mg/time; Time of administration:The drug was given at D 1 and D 182 respectively OLP:Intravenous infusion; Dosage:500mg/time; Time of administration: After D1 dosing, Every 6 months to 1 times

Intravenous infusion; Dosage:500mg/time

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Pharmacodynamics
時間枠:RCP: Day7, Day14, Day28, Day56, Day84, Day112, Day140, Day182, Day280, Day364. OLP:D7, D28, Day84, Day182, Day280, Day364. Week 40+26n (n=1, 2, 3.....) , Week 52+26n (n=1, 2, 3.....). And OLP maximum period for 3 years

The follow-up time point of peripheral blood before and after the analysis to the medicine CD19 + B lymphocytes proportion/count change

RCP: Day7, Day14, Day28, Day56, Day84, Day112, Day140, Day182, Day280, Day364. OLP:D7, D28, Day84, Day182, Day280, Day364. Week 40+26n (n=1, 2, 3.....) , Week 52+26n (n=1, 2, 3.....). And OLP maximum period for 3 years
Pharmacodynamics
時間枠:RCP:in Day84、Day182、Day280、Day364. OLP: in Day1、Day84、Day182、Day280、Day364 of every years.And OLP maximum period for 3 years

Serum immunoglobulin (IgG and IgM) levels were measured.

RCP:in Day84、Day182、Day280、Day364. OLP: in Day1、Day84、Day182、Day280、Day364 of every years.And OLP maximum period for 3 years
Pharmacodynamics
時間枠:RCP:in Day84、Day182、Day280、Day364. OLP: in Day1、Day84、Day182、Day280、Day364 of every years.And OLP maximum period for 3 years

AQP4-IgG levels were measured.

RCP:in Day84、Day182、Day280、Day364. OLP: in Day1、Day84、Day182、Day280、Day364 of every years.And OLP maximum period for 3 years
Pharmacokinetics(PK)
時間枠:Through study completion,up to 49 months. And OLP maximum period for 3 years.

Cmax

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Pharmacokinetics(PK)
時間枠:Through study completion,up to 49 months. And OLP maximum period for 3 years.

Tmax

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Pharmacokinetics(PK)
時間枠:Through study completion,up to 49 months. And OLP maximum period for 3 years.

Cmin

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Pharmacokinetics(PK)
時間枠:Through study completion,up to 49 months. And OLP maximum period for 3 years.

AUC0-tau

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Pharmacokinetics(PK)
時間枠:Through study completion,up to 49 months. And OLP maximum period for 3 years.

t1/2

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Pharmacokinetics(PK)
時間枠:Through study completion,up to 49 months. And OLP maximum period for 3 years.

CL

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Pharmacokinetics(PK)
時間枠:Through study completion,up to 49 months. And OLP maximum period for 3 years.

Vd

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Immunogenicity evaluation
時間枠:RCP:in Day84、Day181、Day252、Day364. OLP: in Day84、Day181、Day252、Day364 of every years.And OLP maximum period for 3 years

Resistant antibody positive rate (ADA)

RCP:in Day84、Day181、Day252、Day364. OLP: in Day84、Day181、Day252、Day364 of every years.And OLP maximum period for 3 years
Immunogenicity evaluation
時間枠:RCP:in Day84、Day181、Day252、Day364. OLP: in Day84、Day181、Day252、Day364 of every years.And OLP maximum period for 3 years

The titers of Ada positive samples

RCP:in Day84、Day181、Day252、Day364. OLP: in Day84、Day181、Day252、Day364 of every years.And OLP maximum period for 3 years

二次結果の測定

結果測定
メジャーの説明
時間枠
Vital signs
時間枠:Through study completion,up to 49 months. And OLP maximum period for 3 years.

Number of participants with abnormal vital signs

Through study completion,up to 49 months. And OLP maximum period for 3 years.
physical examination
時間枠:Through study completion,up to 49 months. And OLP maximum period for 3 years.

Number of participants with abnormal physical examination findings

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Laboratory tests
時間枠:Through study completion,up to 49 months. And OLP maximum period for 3 years.

Number of participants with abnormal laboratory test results

Through study completion,up to 49 months. And OLP maximum period for 3 years.
electrocardiogram( ECG )
時間枠:Through study completion,up to 49 months. And OLP maximum period for 3 years.

Number of participants with abnormal ECG readings

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Adverse events(AE)
時間枠:Through study completion,up to 49 months. And OLP maximum period for 3 years.

Adverse events (AE) is happening, is happening because of adverse events leading to withdrawal Adverse events associated with drugs The occurrence of Serious adverse events (SAE)

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Injection site reactions
時間枠:Through study completion,up to 49 months. And OLP maximum period for 3 years.

Number of participants with injection site reactions

Through study completion,up to 49 months. And OLP maximum period for 3 years.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Xiangjun Chen, Doctor、Huashan Hospital
  • 主任研究者:Chunfeng Liu, Doctor、Second Affiliated Hospital of Suzhou University
  • 主任研究者:Qun Xue, Doctor、First Affiliated Hospital of Suzhou University
  • 主任研究者:Yan Jiang, Doctor、Anhui Provincial Hospital
  • 主任研究者:Yuying Zhao, Doctor、Shandong University Qilu Hospital
  • 主任研究者:Li Guo, Doctor、Second Hebei Medical University Hospital
  • 主任研究者:Meini Zhang, Doctor、The First Affiliated Hospital of Shanxi Medical University
  • 主任研究者:Huan Yang, Doctor、The Central South University Xiang Ya Hospital
  • 主任研究者:Daishi Tian, Doctor、Tongji hospital affiliated to Tongji Medical College
  • 主任研究者:Yuming Xu, Doctor、The First Affiliated Hospital of Zhengzhou University
  • 主任研究者:Jianglong Tu, Doctor、Second Affiliated Hospital of Nanchang University
  • 主任研究者:Wei Qiu, Doctor、The third hospital affiliated to sun yat-sen university
  • 主任研究者:Honghao Wang, Doctor、The First People's Hospital of Guangzhou
  • 主任研究者:Xiaoling Luo, Doctor、Shenzhen city people's hospital
  • 主任研究者:Aiyu Lin, Doctor、First Affiliated Hospital of Fujian Medical University
  • 主任研究者:Chunming Xie, Doctor、China University Hospital of Southeast University
  • 主任研究者:Xiang Li, Doctor、The first hospital affiliated to wenzhou medical college
  • 主任研究者:Lan Tan, Doctor、Qingdao City Hospital
  • 主任研究者:Fudong Shi, Doctor、Tianjin Medical University General Hospital
  • 主任研究者:Jiewen Zhang, Doctor、Henan Provincial People's Hospital
  • 主任研究者:Jing Ding, Doctor、Shanghai Zhongshan Hospital
  • 主任研究者:Ping Chen, Doctor、Xianyang yanan university hospital co., LTD
  • 主任研究者:Zunbo Li, Doctor、Xi'an high-tech Hospital Co. , Ltd.
  • 主任研究者:Qihe Dai, Doctor、Jingzhou city central hospital
  • 主任研究者:Dan Liu, Doctor、the first hospital of Baotou medicine college
  • 主任研究者:Junyan Liu, Doctor、Hebei Medical University Third Hospital
  • 主任研究者:Yiqi Wang, Doctor、Zhejiang Province People's Hospital
  • 主任研究者:Bo Hu, Doctor、Xiehe hospital affiliated to tongji medical college
  • 主任研究者:Yanbing Han, Doctor、First Affiliated Hospital of the Kunming Medical University
  • 主任研究者:Feng Wang, Doctor、Wuxi city people's hospital
  • 主任研究者:Zhanhua Liang, Doctor、The First Affiliated Hospital of Dalian Medical University
  • 主任研究者:Weihe Zhang, Doctor、Sino-Japanese Friendship Hospital
  • 主任研究者:Xiangyang Zhu, Doctor、Nantong First People's Hospital
  • 主任研究者:Xinfeng Liu, Doctor、The Chinese people's liberation army general hospital in eastern theater
  • 主任研究者:Weidong Pan, Doctor、Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
  • 主任研究者:Wei Lu, Doctor、The Central South University Xiang YA II hospital
  • 主任研究者:Huiyu Feng, Doctor、The first hospital affiliated to sun yat-sen university
  • 主任研究者:Yamei Tang, Doctor、Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
  • 主任研究者:Juming Yu, Doctor、Affiliated Hospital of North Sichuan Medical College
  • 主任研究者:Jun Guo, Doctor、The Second Affiliated Hospital of the PLA Air Force Military Medical University
  • 主任研究者:Yanghua Tian, Doctor、The Second Hospital of Anhui Medical University
  • 主任研究者:Feng Gao, Doctor、The first hospital of Peking University
  • 主任研究者:Yun Xu, Doctor、Drum tower hospital affiliated to nanjing university school of medicine

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年8月1日

一次修了 (推定)

2027年12月31日

研究の完了 (推定)

2027年12月31日

試験登録日

最初に提出

2023年7月31日

QC基準を満たした最初の提出物

2023年9月12日

最初の投稿 (実際)

2023年9月21日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月2日

QC基準を満たした最後の更新が送信されました

2026年9月29日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • BAT-4406F-002-CR

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する